| 形态 | Liquid |
|---|
| 宿主种属 | Human |
|---|
| 克隆性 | Monoclonal |
|---|
| 抗体亚型 | IgG4-IgG1, Lambda |
|---|
| 纯度 | >95% purity as determined by SDS-PAGE. |
|---|
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
|---|
| 浓度 | 2.35mg/ml |
|---|
| 内毒素水平 | Please contact the lab for this information. |
|---|
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| 种属反应性 | Human |
|---|
| 靶标 | OSMRB, IL-31R subunit beta, Oncostatin-M-specific receptor subunit beta, Interleukin-31 receptor subunit beta, IL-31RB, IL-31R-beta, OSMR, IL-31 receptor subunit beta |
|---|
| 储存缓冲液 | 0.01M PBS, pH 7.4. |
|---|
| 稳定性和储存 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| 表达系统 | Mammalian Cells |
|---|
| 登录号 | Q99650 |
|---|
| 背景信息 | Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash.<br>• Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma., PMID:34087162<br/>• Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease., PMID:28368383<br/>• Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth., PMID:34380633<br/>• Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology., PMID:26198770<br/>• The Role of Oncostatin M and Its Receptor Complexes in Cardiomyocyte Protection, Regeneration, and Failure., PMID:35163735<br/>• Oncostatin M Induces a Pro-inflammatory Phenotype in Intestinal Subepithelial Myofibroblasts., PMID:38717842<br/>• Engineered interleukin-6-derived cytokines recruit artificial receptor complexes and disclose CNTF signaling via the OSMR., PMID:38569939<br/>• AHNAK, regulated by the OSM/OSMR signaling, involved in the development of primary localized cutaneous amyloidosis., PMID:37100691<br/>• Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma., PMID:24659184<br/>• Targeting OSMR in glioma stem cells., PMID:28177884<br/> |
|---|
| 别名 | KPL-716, 30C6(N73D), BIIB069, BIIB-069, 2243320-83-2 |
|---|
| 备注 | For research use only. Not suitable for clinical or therapeutic use. |
|---|